Subject Insights to Understand the Hand Osteoarthritis (HOA)
Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Hand Osteoarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Cheshire
-
Bollington, Cheshire, United Kingdom, SK10 5JB
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion Criteria for Erosive Hand OA
- Subject is a male or female between 40-80 years of age (inclusive) at the time of signing the informed consent form.
- Subject meets the American College of Rheumatology (ACR) classification of osteoarthritis: Hand pain, aching, or stiffness and 3 or 4 of the following features: Hard tissue enlargement of 2 or more of 10 selected joints, Hard tissue enlargement of 2 or more distal interphalangeal (DIP) joints, Fewer than 3 swollen metatarsophalangeal (MCP) joints or Deformity of at least 1of 10 selected joints where The 10 selected joints are the second and third DIP, the second and third proximal interphalangeal (PIP), and the first carpometacarpal joints of both hands.
- Subject has erosive disease on at least 1 PIP or 1DIP joint as demonstrated by imaging evidence [can include X-ray, ultrasound or magnetic resonance imaging (MRI) evidence].
- Subject has active disease in at least one hand, with at least two soft tissue swollen and tender PIP and/or DIP joints in the affected hand by clinical examination within the past 3 months. If only one hand is affected by HOA and meets the inclusion criteria, the affected hand should be documented at screening and used for all assessments. In cases where both hands are affected by HOA and both meet the inclusion criteria, then the dominant hand should be documented at screening and used for all assessments.
- Subject's self-reported average hand-pain intensity over the past 7 days must be at least '4' on a 0-10 Numerical Rating Scale (NRS).
- Subject must have negative titer rheumatoid factor (RF) and anti- Cyclic Citrullinated Peptide (CCP) antibody.
- Subject must have a personally signed and dated written informed consent form prior to admission to the study.
- Subject must be verbally fluent and literate in English.
- Subject must be able to attend and participate in two 45 minute telephone or video call (Skype or Facetime) interviews (either on the same day or separate days).
Inclusion Criteria for Non-Erosive Hand OA
- Subject is a male or female between 40-80 years of age (inclusive) at the time of signing the informed consent form
- Subject meets the American College of Rheumatology (ACR) classification of osteoarthritis: Hand pain, aching, or stiffness and 3 or 4 of the following features: Hard tissue enlargement of 2 or more of 10 selected joints, Hard tissue enlargement of 2 or more distal interphalangeal (DIP) joints, Fewer than 3 swollen metacarpophalangeal (MCP) joints, Deformity of at least 1 of 10 selected joints where the 10 selected joints are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands.
- Subject has at least 1 finger joint (DIP or PIP) with K-L ≥ 2 [by x-ray in last 12m]. Participant's self-reported average hand-pain intensity over the past 7 days must be moderate to severe (≥4 on a 0-10 Numeric Rating Scale [NRS] or ≥40mm on a 0-100mm Visual Analog Scale [VAS]). If only one hand is affected by hand osteoarthritis (HOA) and meets the inclusion criteria, the affected hand should be documented at screening and used for all assessments. In cases where both hands are affected by HOA and both meet the inclusion criteria, then the dominant hand should be documented at screening and used for all assessments.
- Subject is unwilling or unable to take non-opiate analgesics, or is inadequately controlled by non-opiate analgesics (non-opiate analgesics include Tramadol)
- Subject must have negative titer rheumatoid factor (RF) and anti-CCP antibody
- Subject must have a personally signed and dated written informed consent form prior to admission to the study
- Subject must be verbally fluent and literate in English
- Subject must be able to attend and participate in two 45 minute telephone or video call (Skype or Facetime) interviews (either on the same day or separate days)
Inclusion criteria for subjects taking part in real-time data capture:
- Subject owns/or has access to either a smartphone [iPhone Operating System (iOS) or android] or tablet which has video, audio/microphone and photographic capabilities and access to either the Apple app store or Google play store to download the app.
- Subject is willing and able to take part in the real time data application task and respond to a series of questions/tasks fielded via the application over the course of seven days.]
- Subject would feel comfortable recording short videos of themselves and providing audio commentary in response to app questions/tasks.
Exclusion Criteria:
Exclusion Criteria for Erosive Hand OA
- Subject has history of any clinically significant inflammatory disease other than inflammatory osteoarthritis, especially, but not limited to, rheumatoid arthritis or spondylarthropathies.
- Subject has a diagnosis of rheumatoid arthritis, fibromyalgia, gout, calcium pyrophosphate deposition disease (CPPD), pseudogout, hemochromatosis or other inflammatory rheumatological or autoimmune disorders.
- Subject has had a clinical suspicion of, or previous investigation for CPPD or pseudogout, or history of chondrocalcinosis.
- Subject has any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand osteoarthritis joint(s).
- Subject has great difficulty hearing, reading or speaking.
- Subject has an uncontrolled psychiatric condition (example, schizophrenia,bipolar disorder) or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study or likely to have difficulty participating in two 45 minute interviews.
- Subject has severe physical, neurological or cognitive deficits that might prohibit the ability to participate in an interview about the experience of their hand osteoarthritis and completion of a questionnaire.
- Subject is currently or has previously been enrolled in a clinical trial for OA in the past 6 months.
Exclusion Criteria for Non-Erosive Hand OA
- Subject has erosive disease on any proximal interphalangeal (PIP) or distal interphalangeal (DIP) joints as evidenced via X-ray, MRI or ultrasound
- Subject has history of any clinically significant inflammatory disease other than inflammatory osteoarthritis, especially, but not limited to, rheumatoid arthritis or spondylarthropathies
- Subject has a diagnosis of rheumatoid arthritis, fibromyalgia, gout, calcium pyrophosphate deposition disease (CPPD), pseudogout, hemochromatosis or other inflammatory rheumatological or autoimmune disorders
- Subject has had a clinical suspicion of, or previous investigation for CPPD or pseudogout, or history of chondrocalcinosis
- Subject has any injury, medical or surgical procedure to the affected joint(s) that may interfere with evaluation of the target hand osteoarthritis joint(s)
- Subject has great difficulty hearing, reading or speaking
- Subject has an uncontrolled psychiatric condition (e.g., schizophrenia, bipolar disorder) or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study or likely to have difficulty participating in two 45 minute interviews
- Subject has severe physical, neurological or cognitive deficits that might prohibit the ability to participate in an interview about the experience of their hand osteoarthritis and completion of a questionnaire
- Subject is currently or has previously been enrolled in a clinical trial for hand OA in the past six months
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Subjects participating in the CE and CD interview
Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
|
The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s).
The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function.
In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
|
|
Subjects participating in interview and real time data capture
Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
|
The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s).
The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function.
In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with hand osteoarthritis participating in CE interviews
Time Frame: 1 day
|
CE interviews will be carried out to explore disease experience with respect to symptoms, impacts and treatment/surgical experiences.
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Content validity of the Michigan Hand Outcomes Questionnaire through CD interviews
Time Frame: 1 day
|
The MHQ is a self-report measure that assesses the function of hand(s) and/or wrist(s).
The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function.
In a pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
Subjects will be asked to complete the MHQ questionnaire during CD interview using a 'think-aloud' technique to evaluate the content validity.
|
1 day
|
|
Analysis of hand osteoarthritis experience by using real-time data data capture task
Time Frame: Up to 7 days
|
A subgroup of ten of the thirty subjects participating in the CE and CD interviews will be asked to take part in the real-time data capture task over the course of 7 days and during this time a series of questions/tasks will be asked to subjects via the application to explore the experience of the symptoms, HRQoL impacts and treatment of erosive HOA and any day-to-day variability that exists these experiences in 'real time'.
|
Up to 7 days
|
|
Preparation of conceptual model
Time Frame: Up to 7 days
|
Data obtained from the CE and CD interviews as well as real-time data capture will be used to develop a conceptual model for erosive HOA.
Symptom, impact, and treatment concepts which have been identified will be grouped into domains and displayed visually and any identified relationships or trends between domains will also be included in the model.
A key will be developed using color coding or bolding/italics to show the source of the concept (example, red if the concept emerged from the interviews only, and green it emerged from the real-time data capture only).
In addition, and where relevant the frequency at which a concept was reported across sources will be included in the model.
|
Up to 7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 206599
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
NCT07458971Not yet recruitingThumb Osteoarthritis | Trapeziometacarpal Osteoarthritis | Carpometacarpal Osteoarthritis | Thumb Basal Joint Osteoarthritis
-
NCT04405297TerminatedKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist Osteoarthritis
-
NCT06717529CompletedOsteoarthritis | Osteoarthritis of the Knee | Osteoarthritis of Knee | Osteoarthritis of the Knees | Osteoarthritis (OA) of the Knee | Osteoarthritis Knee | Osteoarthritis in the Knee | Osteoarthritis of Knee Joint
-
NCT05675618RecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis
-
NCT07324746RecruitingOsteoarthritis | Osteoarthritis (OA) | Osteoarthritis (OA) of the Knee | Osteoarthritis (OA) of the Hip
-
NCT07551856Not yet recruitingOsteoarthritis | Knee Osteoarthritis | Osteoarthritis (OA) | Osteo Arthritis | Osteoarthritis in the Knee | Osteoarthritis (Knee) | Osteo Arthritis of the Knee
-
NCT05676567Active, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis
-
NCT03869229UnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral Osteoarthritis
-
NCT03866330UnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral Osteoarthritis
-
NCT07212647CompletedKnee Osteoarthritis | Knee Osteoarthritis (Knee OA)
Clinical Trials on Michigan Hand Outcomes Questionnaire
-
NCT06887530CompletedCerebral Palsy (CP) | Hand Functions
-
NCT04243590CompletedCerebral Palsy | Brachial Plexus Palsy
-
NCT02705846Recruiting
-
NCT06188572Completed
-
NCT07101146Not yet recruiting
-
NCT02567266CompletedDepression | Anxiety
-
NCT04062305Active, not recruitingMetastatic Malignant Neoplasm in the Brain | Radiation Therapy Recipient
-
NCT03956147CompletedShoulder Pain | Shoulder Injury | Shoulder Impingement
-
NCT05263128WithdrawnCarpal Tunnel Syndrome